Medical sector’s Sarepta Therapeutics’s (NASDAQ:SRPT) Buy rating Reiterated by SVB Leerink LLC – 4 stars

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its Buy rating Reiterated by analysts at SVB Leerink LLC – 4 stars in a research report issued to clients and investors. A price-to-earnings ratio of #N/A, market cap of 7.3B and a beta of 1.42.  Sarepta Therapeutics has a twelve month low $65.30 of  and a twelve month high of $181.83.

Shares of Sarepta Therapeutics traded down -$8.13 on monday, reaching $91.29. 28,793 shares of the stock traded hands, compared to its average volume of 849358. Shares of Sarepta Therapeutics at close on monday were at $91.29. The firm’s 50 day moving average is $$82.67 and its 200 day moving average is $84.33.Sarepta Therapeutics  has a 12 month low of $90.51 and a 12 month high of $181.83. While on yearly highs and lows, Sarepta Therapeutics’s today has traded high as $97.95 and has touched $90.51 on the downward trend. See More Analyst Rating at: RATING

Sarepta Therapeutics (NASDAQ:SRPT) Moving Average Technical Analysis

5 day Moving Average is $95.63 And 5 day price change is -$3.37 (-3.56%)  with average volume for 5 day average is 1,306,660. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $90.57 and 20 day price change is $9.45 (11.55%) and average 20 day moving volume is 1,008,395. 50 day moving average is $82.67  and 50 day price change is $23.51 ( 34.69%)  and with average volume for 50 days is : 849,266. 200 day moving average is $84.33  and 200 day price change is -$86.77 (-48.73%)  and with average volume for 200 days is : 1,324,134.

See More Analyst Rating at: RATING

Sarepta Therapeutics Earnings and What to expect: 

Sarepta Therapeutics last announced its earnings results on August 4th, 2021. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.27. The firm had revenue of $164.09 million for the quarter, compared to analyst estimates of $161.95 million. Its quarterly revenue was up 19.5% on a year-over-year basis. Sarepta Therapeutics has generated ($7.11) earnings per share over the last year (($8.02) diluted earnings per share). Earnings for Sarepta Therapeutics are expected to grow in the coming year, from ($7.46) to ($6.11) per share. Sarepta Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Sarepta Therapeutics are expected to grow in the coming year, from ($7.46) to ($6.11) per share. The P/E ratio of Sarepta Therapeutics is -11.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Sarepta Therapeutics is -11.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Sarepta Therapeutics has a P/B Ratio of 9.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Other owners latest trading in Sarepta Therapeutics :

  • On 10/5/2021 shares held by IBM Retirement Fund were 2,181 which equates to market value of $0.20M and appx 0.00% owners of Sarepta Therapeutics
  • On 9/24/2021 shares held by Thrivent Financial for Lutherans were 104,155 which equates to market value of $8.10M and appx 0.00% owners of Sarepta Therapeutics
  • On 9/17/2021 shares held by Virtu Financial LLC were 5,612 which equates to market value of $0.44M and appx 0.00% owners of Sarepta Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 79.33% for Sarepta Therapeutics

See More Analyst Rating at: RATING